BRIEF—HitGen and SPARC enter into R&D collaboration

HitGen and Sun Pharma Advanced Research Company (SPARC) are to collaborate to identify novel small molecule leads for targets of interest.

HitGen will apply its tech based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC. HitGen will receive an upfront payment and will be eligible for certain milestone payments.

SPARC, the innovative R&D arm of Sun Pharma, is headquartered in Mumbai. HitGen is based in Chengdu, China.